{
  "title": "Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study.",
  "pmid": "40759444",
  "doi": null,
  "affiliations": [
    "Université Bourgogne Europe, Dijon, France fghiringhelli@cgfl.fr.",
    "Early Clinical Trial Unit, Centre Georges-Francois Leclerc, Dijon, France.",
    "The Benjamin Davidai Department of Radiation Oncology, Sheba Medical Center, Tel HaShomer, Israel.",
    "Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.",
    "Institute of Oncology, Rambam Health Campus, Haifa, Israel.",
    "APHM, INSERM, CNRS, CRCM, Hôpital Nord, Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille Université, Marseille, France.",
    "Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK.",
    "Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.",
    "F Hoffmann-La Roche Ltd, Basel, Switzerland.",
    "F Hoffmann-La Roche Ltd, Basel, Switzerland.",
    "Genentech Inc, South San Francisco, California, USA.",
    "F Hoffmann-La Roche Ltd, Basel, Switzerland.",
    "Queen Mary University of London, London, UK.",
    "Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of).",
    "Yonsei Cancer Center, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of)."
  ]
}